Agendia expands laboratory capacity

Agendia announced the official opening of its new headquarters at Amsterdam's Science Park at Watergraafsmeer, Kruislaan 406. The Grand Opening ceremony was officiated by Dr. Rene Bernards, Chief Scientific Officer at Agendia and the Honourable Director General Mrs. R.M. Bergkamp, on behalf of the Honourable Mrs. Maria van der Hoeven, Minster of Economic Affairs for The Netherlands.

“Agendia has a distinguished history of providing exceptional high quality diagnostic testing services that provide valuable information for cancer patients and the physicians who treat them," said Dr. Bernhard Sixt, Agendia’s president & chief executive officer (CEO). "The expanded capacity of our laboratories at our new location will allow us to meet the growing worldwide demand for our clinical services as we expand into major markets, enhancing the company's ability to serve the healthcare community."

The new facilities offer 13,000 square feet of laboratory and office space that will support the company's molecular diagnostic cancer testing services and research activities.

“Additionally, this move proves our ability to replicate our FDA-cleared and CLIA-certified laboratory in a new location in just four months,” said Dr. Jan Groen, vice president and chief operating officer (COO) at Agendia. “The increased laboratory space will also allow the company to expand our research and product development capabilities to enhance commercialization of emerging diagnostic discoveries in cancer."

Currently, Agendia offers three test services through its expanded laboratories, including MammaPrint, based on the Amsterdam 70-gene profile, that indicates risk of recurrence for breast cancer tumors and the first in vitro diagnostic multi-variant index assay (IVDMIA) cleared by the U.S. Food and Drug Administration (FDA), and CupPrint*, which identifies the origin of metastases with unknown primary tumors (Cancer of Unknown Primary).
 

19.07.2009

Read all latest stories

Related articles

Photo

Article • IVD Market

Santa’s bag full of cash

We are seeing great priority shifts in China’s funding for R&D and manufacturing expansion. Even the agency responsible for selecting the recipients has changed, Jie Ren reports from the…

Photo

News •

Cautiously optimistic

Despite a slight drop in sales in 2013 compared to the previous year, for 2014 the German medical diagnostics manufacturers anticipate a positive business development, according to the trend…

Photo

News •

GE to expand in fast-growing Life Sciences sectors

GE and Thermo Fisher Scientific announced yesterday that they have entered into an agreement for GE Healthcare to acquire Thermo Fisher’s HyClone cell culture media and sera, and gene modulation…

Related products

Subscribe to Newsletter